CN109689056A - 用于治疗癌症的组合 - Google Patents

用于治疗癌症的组合 Download PDF

Info

Publication number
CN109689056A
CN109689056A CN201780056390.6A CN201780056390A CN109689056A CN 109689056 A CN109689056 A CN 109689056A CN 201780056390 A CN201780056390 A CN 201780056390A CN 109689056 A CN109689056 A CN 109689056A
Authority
CN
China
Prior art keywords
cancer
carcinoma
subject
ctla
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780056390.6A
Other languages
English (en)
Chinese (zh)
Inventor
埃里克·桑托斯·马丁
横山由美
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ignyta Inc
Original Assignee
Ignyta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ignyta Inc filed Critical Ignyta Inc
Publication of CN109689056A publication Critical patent/CN109689056A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201780056390.6A 2016-08-01 2017-07-28 用于治疗癌症的组合 Pending CN109689056A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662369639P 2016-08-01 2016-08-01
US62/369,639 2016-08-01
PCT/US2017/044513 WO2018026663A1 (en) 2016-08-01 2017-07-28 Combinations for the treatment of cancer

Publications (1)

Publication Number Publication Date
CN109689056A true CN109689056A (zh) 2019-04-26

Family

ID=61073280

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780056390.6A Pending CN109689056A (zh) 2016-08-01 2017-07-28 用于治疗癌症的组合

Country Status (5)

Country Link
US (1) US20190185567A1 (https=)
EP (1) EP3490561A4 (https=)
JP (1) JP2019527231A (https=)
CN (1) CN109689056A (https=)
WO (1) WO2018026663A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
EA201991650A1 (ru) 2017-01-06 2020-01-20 Юманити Терапьютикс, Инк. Способы лечения неврологических расстройств
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
US11247990B1 (en) 2017-12-07 2022-02-15 Array Biopharma Inc Bicyclic fused pyridine compounds as inhibitors of TAM kinases
BR112020019191A2 (pt) 2018-03-23 2021-01-05 Yumanity Therapeutics, Inc. Compostos e seus usos
UY38349A (es) 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
MX2021008903A (es) 2019-01-24 2021-11-04 Yumanity Therapeutics Inc Compuestos y usos de los mismos.
WO2020198026A1 (en) * 2019-03-22 2020-10-01 Yumanity Therapeutics, Inc. Compounds and uses thereof
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
AU2019474803B2 (en) * 2019-11-19 2024-11-07 Provectus Pharmatech, Inc. Composition and method for treating hematologic cancers
US11419844B2 (en) 2019-11-19 2022-08-23 Provectus Pharmatech, Inc. Halogenated xanthene composition and method for treating hematologic cancers

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009202447A1 (en) * 1999-08-24 2009-07-09 E. R. Squibb & Sons, L.L.C. Human CTLA-4 antibodies and their uses
WO2012027536A1 (en) * 2010-08-26 2012-03-01 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with braf inhibitors for the synergistic treatment of proliferative diseases
CN102822200A (zh) * 2009-07-20 2012-12-12 百时美施贵宝公司 对增殖性疾病进行协同性治疗的抗ctla-4抗体与各种治疗方案的组合
CN103958497A (zh) * 2011-11-14 2014-07-30 赛福伦公司 作为AXL和c-MET激酶抑制剂的尿嘧啶衍生物
CN105683197A (zh) * 2013-08-02 2016-06-15 亚尼塔公司 单独地或与其它试剂联合地使用AXL/cMET抑制剂治疗多种癌症的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015203322B2 (en) * 2009-07-20 2016-09-29 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
EP2714081A4 (en) * 2011-05-27 2015-09-09 Cytocure Llc METHODS, COMPOSITIONS AND KIT FOR CREAM TREATMENT
WO2015116868A2 (en) * 2014-01-29 2015-08-06 Caris Mpi, Inc. Molecular profiling of immune modulators
US10231965B2 (en) * 2014-02-20 2019-03-19 Ignyta, Inc. Molecules for administration to ROS1 mutant cancer cells

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009202447A1 (en) * 1999-08-24 2009-07-09 E. R. Squibb & Sons, L.L.C. Human CTLA-4 antibodies and their uses
CN102822200A (zh) * 2009-07-20 2012-12-12 百时美施贵宝公司 对增殖性疾病进行协同性治疗的抗ctla-4抗体与各种治疗方案的组合
WO2012027536A1 (en) * 2010-08-26 2012-03-01 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with braf inhibitors for the synergistic treatment of proliferative diseases
CN103958497A (zh) * 2011-11-14 2014-07-30 赛福伦公司 作为AXL和c-MET激酶抑制剂的尿嘧啶衍生物
CN105683197A (zh) * 2013-08-02 2016-06-15 亚尼塔公司 单独地或与其它试剂联合地使用AXL/cMET抑制剂治疗多种癌症的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HIROYUKI WATANABE等: ""Prognostic Value of Hepatocyte Growth Factor Receptor Expression in Patients with Perihilar Cholangiocarcinoma"", 《ANNALS OF SURGICAL ONCOLOGY》 *

Also Published As

Publication number Publication date
US20190185567A1 (en) 2019-06-20
EP3490561A4 (en) 2020-04-08
WO2018026663A1 (en) 2018-02-08
EP3490561A1 (en) 2019-06-05
JP2019527231A (ja) 2019-09-26

Similar Documents

Publication Publication Date Title
CN109689056A (zh) 用于治疗癌症的组合
CN109715157A (zh) 用于治疗癌症的组合
US11986484B2 (en) 17α-monoesters and 17α,21-diesters of cortexolone for use in the treatment of tumors
CN109789146A (zh) 趋化因子受体调节剂及其用途
USRE50319E1 (en) Compounds and methods for treating cancer
TW202131930A (zh) 抗癌核荷爾蒙受體標靶化合物
CN108712904A (zh) 2-(4-氯苯基)-n-((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2,2-二氟乙酰胺的固体形式以及其药物组合物和用途
CN109223791A (zh) 脑癌的治疗
CN109819649A (zh) (1s,4s)-4-(2-(((3s,4r)-3-氟四氢-2h-吡喃-4-基)氨基)-8-((2,4,6-三氯苯基)氨基)-9h-嘌呤-9-基)-1-甲基环己烷-1-甲酰胺的固体形式及其使用方法
JPWO2016104657A1 (ja) 癌治療剤
EP3922251A1 (en) Cancer immunotheraphy adjuvant
KR20220130085A (ko) 테트라사이클릭 화합물 및 이의 염, 조성물, 및 이의 사용 방법
KR102619415B1 (ko) 안드로겐 박탈 요법 연관 증상의 치료
JP2025028945A (ja) ビスホスホネート連結化合物
TW201806970A (zh) 嵌合抗原受體、及其利用
US20140275234A1 (en) Compositions and methods of using crystalline forms of wortmannin analogs
WO2021046178A1 (en) Compounds and methods for treating cancer
US10857113B2 (en) Bezafibrate for the treatment of cancer
WO2024222662A1 (zh) 一种抗体偶联药物的用途
WO2025132831A1 (en) N-heteroaryl derivatives and uses thereof for treating cancer
CN114522170A (zh) 靶向adora2a受体的拮抗剂在制备治疗神经内分泌肿瘤的药物中的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40005273

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190426

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 40005273

Country of ref document: HK